Cargando…

Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools

The drug concentrations targeted in meropenem and piperacillin/tazobactam therapy also depend on the susceptibility of the pathogen. Yet, the pathogen is often unknown, and antibiotic therapy is guided by empirical targets. To reliably achieve the targeted concentrations, dosing needs to be adjusted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weinelt, Ferdinand Anton, Stegemann, Miriam Songa, Theloe, Anja, Pfäfflin, Frieder, Achterberg, Stephan, Weber, Franz, Dübel, Lucas, Mikolajewska, Agata, Uhrig, Alexander, Kiessling, Peggy, Huisinga, Wilhelm, Michelet, Robin, Hennig, Stefanie, Kloft, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219867/ https://www.ncbi.nlm.nih.gov/pubmed/35740164 http://dx.doi.org/10.3390/antibiotics11060758

Ejemplares similares

Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing—A Translational Example for Intensive Care Units
por: Weinelt, Ferdinand Anton, et al.
Publicado: (2021)

Seltene, in Deutschland nicht endemische Infektionen der Lunge
por: Pfäfflin, Frieder, et al.
Publicado: (2020)

Heterogeneous approach to nebulization of antimicrobial agents in mechanically ventilated adults in a German tertiary care hospital: a cross-sectional survey
por: Pfäfflin, Frieder, et al.
Publicado: (2020)

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients
por: Liebchen, Uwe, et al.
Publicado: (2021)

Preparing for patients with high-consequence infectious diseases: Example of a high-level isolation unit
por: Pfäfflin, Frieder, et al.
Publicado: (2022)

No clinically relevant removal of meropenem by cytokine adsorber CytoSorb(®) in critically ill patients with sepsis or septic shock
por: Liebchen, Uwe, et al.
Publicado: (2021)

CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Meropenem/piperacillin/tazobactam: Drug resistance: case report
Publicado: (2021)

Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics
por: Busse, David, et al.
Publicado: (2021)

Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients
por: Busse, David, et al.
Publicado: (2021)

Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs
por: Barber, Katie E., et al.
Publicado: (2016)

Comparison of Acute Kidney Injury During Treatment with Vancomycin and either Piperacillin-Tazobactam or Meropenem
por: Cannon, John M., et al.
Publicado: (2017)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock()
por: Sun, Yang, et al.
Publicado: (2023)

Monkeypox in-patients with severe anal pain
por: Pfäfflin, Frieder, et al.
Publicado: (2022)

Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data
por: Kluwe, Franziska, et al.
Publicado: (2023)

Comparison of Rates of Acute Kidney Injury with Vancomycin/Piperacillin-Tazobactam vs. Vancomycin/Meropenem Combination Therapy
por: Pernia, Sonia, et al.
Publicado: (2017)

Piperacillin/Tazobactam and Meropenem Use Increases the Risks for Acute Graft Rejection Following First Kidney Transplantation
por: Nasr, Dayana, et al.
Publicado: (2022)

2746. Assessment of in vitro synergy between Piperacillin-Tazobactam-Meropenem and Imipenem-Meropenem against OXA-48 Producing Klebsiella pneumoniae Using Time-Kill Assays
por: Demir, Mervenur, et al.
Publicado: (2023)

Drug-induced hypersensitivity syndrome with high procalcitonin levels due to piperacillin/tazobactam and meropenem: A case report
por: Song, Gao, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice
por: Scharf, Christina, et al.
Publicado: (2020)

Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients—A Controlled Clinical Trial
por: Simon, Philipp, et al.
Publicado: (2020)

Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: Schatz, Lea Marie, et al.
Publicado: (2023)

Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin
por: Busse, David, et al.
Publicado: (2021)

Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study
por: Ehmann, Lisa, et al.
Publicado: (2017)

Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients
por: Heil, Emily, et al.
Publicado: (2017)

1292. Evaluation of Synergy with Piperacillin/Tazobactam plus Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae and Enterobacter cloacae Using ETEST
por: Ashcraft, Deborah S, et al.
Publicado: (2021)

Outbreak of Pandoraea commovens Infections among Non–Cystic Fibrosis Intensive Care Patients, Germany, 2019–2021
por: Kruis, Tassilo, et al.
Publicado: (2023)

1411. Tecioplanin (TEI) vs. Vancomycin (VAN) in Combination with Piperacillin-Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI)
por: Aslan, Abdullah Tarik, et al.
Publicado: (2018)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
por: Berrino, Pasquale Maria, et al.
Publicado: (2023)

Translational Pharmacometric Evaluation of Typical Antibiotic Broad‐Spectrum Combination Therapies Against Staphylococcus Aureus Exploiting In Vitro Information
por: Wicha, SG, et al.
Publicado: (2017)

Cell‐level systems biology model to study inflammatory bowel diseases and their treatment options
por: Stübler, Sabine, et al.
Publicado: (2023)

Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study
por: Joly-Guillou, Marie-Laure, et al.
Publicado: (2010)

486 Meropenem and Piperacillin-tazobactam have Comparable Outcomes in Treatment of Bloodstream Infections Caused by Extended Spectrum Beta-lactamase Producing E.coli and Klebsiellae
por: Harris, Patrick, et al.
Publicado: (2014)

Comparative Risk of Acute Kidney Injury Following Concurrent Administration of Vancomycin with Piperacillin/Tazobactam or Meropenem: A Systematic Review and Meta-Analysis of Observational Studies
por: Alshehri, Abdulmajeed M., et al.
Publicado: (2022)

Exploring Dried Blood Spot Cortisol Concentrations as an Alternative for Monitoring Pediatric Adrenal Insufficiency Patients: A Model-Based Analysis
por: Stachanow, Viktoria, et al.
Publicado: (2022)

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
por: Carlier, Mieke, et al.
Publicado: (2013)

Comparison of Antimicrobial Sensitivity to Older and Newer Quinolones versus Piperacillin-Tazobactam, Cefepime and Meropenem in Febrile Patients with Cancer in two Referral Pediatric Centers in Tehran, Iran
por: Nateghian, AR., et al.
Publicado: (2014)

Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
por: Michelet, Robin, et al.
Publicado: (2023)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Post-treatment haemolysis is common following oral artemisinin combination therapy of uncomplicated malaria in travellers
por: Kurth, Florian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ne52c56vbi4t6u5ld6p96nrh3j